Using a Four-Part RGD Peptide to Image Brain Tumors with PET Scanning
A tetrameric RGD peptide labeled with copper-64 produced clear PET images of brain tumor blood vessels in mice by targeting integrin αvβ3.
Quick Facts
What This Study Found
The tetrameric (four-copy) RGD peptide labeled with copper-64 showed significantly higher integrin binding affinity than monomeric or dimeric versions, likely due to a polyvalency effect. In mice with glioma xenografts, tumor uptake was rapid and high — 9.93 ± 1.05 %ID/g at 30 minutes — with slow washout (4.56 ± 0.51 %ID/g at 24 hours).
Blood clearance was fast (0.21 %ID/g at 4 hours), and the probe was excreted mainly through the kidneys. Blocking experiments with excess RGD confirmed that tumor uptake was specifically mediated through integrin αvβ3. Dosimetry estimates suggested acceptable radiation exposure for potential human use, with an effective dose of 0.0164 mSv/MBq.
Key Numbers
How They Did This
Researchers synthesized a tetrameric RGD peptide conjugated to a DOTA chelator and labeled it with copper-64 for PET imaging. They tested integrin binding affinity in vitro, then performed biodistribution studies and microPET imaging in female athymic nude mice bearing subcutaneous U87MG glioma xenografts. Metabolic stability was assessed in blood, urine, liver, and kidney homogenates. Blocking studies with excess cold RGD peptide confirmed target specificity. Human radiation dosimetry was estimated from the mouse biodistribution data.
Why This Research Matters
Integrin αvβ3 is overexpressed on the blood vessels that tumors recruit to feed their growth. Being able to image this marker non-invasively could help doctors detect tumors, monitor anti-angiogenic therapy, and select patients for integrin-targeted treatments. This study was an early demonstration that multimerizing RGD peptides dramatically improves their tumor-targeting ability — a design principle that influenced subsequent peptide-based imaging agents.
The Bigger Picture
RGD peptide imaging has become a significant area of nuclear medicine research, with several tracers now in clinical trials for detecting various cancers. This 2005 study was part of the early wave demonstrating that multivalent peptide designs could dramatically improve tumor targeting. The approach of using peptides rather than antibodies for molecular imaging offers advantages in faster blood clearance and better tumor-to-background ratios — principles that continue to guide peptide radiopharmaceutical development today.
What This Study Doesn't Tell Us
This was a preclinical study using a single mouse tumor model (subcutaneous glioma xenografts), which does not fully replicate human brain tumor biology. Metabolic stability was modest, with only about 70% intact tracer in blood at 1 hour. The subcutaneous tumor location differs from the actual intracranial setting where the blood-brain barrier would affect tracer delivery. Human dosimetry was estimated from mouse data, not measured directly.
Questions This Raises
- ?How does this tetrameric RGD tracer perform in orthotopic (intracranial) brain tumor models where the blood-brain barrier is a factor?
- ?Could gallium-68 or fluorine-18 labeling improve the clinical translatability of multimeric RGD peptide tracers?
- ?Has this specific tracer or its derivatives advanced to human clinical imaging studies?
Trust & Context
- Key Stat:
- 9.93 %ID/g tumor uptake At 30 minutes post-injection, showing rapid and high accumulation in integrin-positive glioma tumors
- Evidence Grade:
- This is a preclinical study in a mouse xenograft model. While it provides rigorous in vitro and in vivo characterization with appropriate controls (blocking studies, dosimetry), the findings have not yet been validated in humans.
- Study Age:
- Published in 2005, this is an early and influential study in multivalent RGD peptide imaging. The specific tracer design concepts remain relevant, though the field has since moved toward gallium-68 and fluorine-18 labeled tracers for clinical use.
- Original Title:
- microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
- Published In:
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 46(10), 1707-18 (2005)
- Authors:
- Wu, Yun, Zhang, Xianzhong, Xiong, Zhengming, Cheng, Zhen, Fisher, Darrell R, Liu, Shuang, Gambhir, Sanjiv S, Chen, Xiaoyuan
- Database ID:
- RPEP-01101
Evidence Hierarchy
Frequently Asked Questions
What is an RGD peptide and why is it useful for cancer imaging?
RGD is a three-amino-acid sequence (arginine-glycine-aspartate) that binds tightly to integrin αvβ3, a protein found on the new blood vessels that tumors grow. By attaching a radioactive label to RGD peptides, researchers can create PET tracers that home in on tumors and make them visible on scans — potentially helping detect cancers and monitor treatment response.
Why does having four copies of the RGD peptide work better than one?
Integrins often cluster together on cell surfaces. When a tracer has four RGD copies, multiple copies can bind simultaneously to nearby integrins, dramatically increasing the overall binding strength (a polyvalency effect). This results in more tracer accumulating in the tumor and staying there longer, producing clearer PET images.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01101APA
Wu, Yun; Zhang, Xianzhong; Xiong, Zhengming; Cheng, Zhen; Fisher, Darrell R; Liu, Shuang; Gambhir, Sanjiv S; Chen, Xiaoyuan. (2005). microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 46(10), 1707-18.
MLA
Wu, Yun, et al. "microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.." Journal of nuclear medicine : official publication, 2005.
RethinkPeptides
RethinkPeptides Research Database. "microPET imaging of glioma integrin {alpha}v{beta}3 expressi..." RPEP-01101. Retrieved from https://rethinkpeptides.com/research/wu-2005-micropet-imaging-of-glioma
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.